Rebiotix Sitemap
- Home
- About Rebiotix
- Our Therapy
- Rebiotix Product Pipeline
- Schedule a Stool Donor Screening
- Clinical Trials
- Scientific Evidence
- News & Media
- Contact Us
- Terms of Use
- Privacy Policy
- Sitemap
- Microbiota Restoration Therapy Abstracts
- Microbiome and Bile Acid Restoration was Consistent Across Three Clinical Trials of RBX2660 for Recurrent Clostridioides Difficile Infection: A Combined Analysis
- RBX2660, an Investigational Live Microbiota-based Biotherapeutic, Improves Outcomes of Clostridioides difficile Infection in a Real-World Population: A Retrospective Study of Use Under Enforcement Discretion
- Efficacy of Investigational Microbiota-Based Live Biotherapeutic RBX2660 in Individuals with Recurrent Clostridioides difficile Infection: Data from Five Prospective Clinical Studies
- Treatment Success in Reducing Recurrent Clostridioides difficile Infection with Investigational Live Biotherapeutic RBX2660 is Associated with Microbiota Restoration: Consistent Evidence from a Phase 3 Clinical Trial
- Safety of Investigational Microbiota-Based Live Biotherapeutic RBX2660 in Individuals with Recurrent Clostridioides difficile Infection: Data From Five Prospective Clinical Studies
- Antimicrobial Resistance Genes were Reduced Following Administration of Investigational Live Biotherapeutic RBX2660 to Individuals with Recurrent Clostridioides difficile Infection
- Rapid Restoration of Bile Acid Compositions After Treatment with RBX2660 for Recurrent Clostridioides difficile Infection—Results from the PUNCH CD3 Phase 3 Trial
- Developing Microbiome Rehabilitation Biomarkers for Clostridium difficile Infections: Evaluation and Plan of a Prototype MICROBIOME HEALTH INDEX™ (MHI™)
- Prevention of Recurrent Clostridioides difficile Infection at Two Years After Treatment with Investigational Microbiota-Based Drug RBX2660: Efficacy, Durability, Microbiome Changes, and Participant Demographics of a Phase 2 Open-Label Clinical Trial 
- Rapid Restoration of Bile Acid Compositions After Treatment with Investigational Microbiota-Based Therapeutic RBX2660 For Recurrent Clostrioides difficile Infection
- Antimicrobial Resistance Genes Are Reduced Following Administration of Investigational Microbiota-Based Therapeutic RBX7455 to Individuals with Recurrent Clostrioides difficile Infection
- A Prototype Biomarker for Microbiome Rehabilitation in Patients with Clostridium difficile Infections: Application to a Clinical Trial of a Lyophilized, Non-Frozen, Oral, Microbiota-Based Drug RBX7455
- A Lyophilized, Non-Frozen, Oral Microbiota-Based Drug RBX7455 is Safe, Reduces Clostridium difficile Infection Recurrence, and Restores the Microbiome
- Developing Microbiome Rehabilitation Biomarkers for Clostridium Difficle Infections: Continued Evaluation of a Prototype MICROBIOME HEALTH INDEX™ (MHI™)
- Developing Microbiome Rehabilitation Biomarkers for Clostridium difficile Infections: Evaluation of a Prototype MICROBIOME HEALTH INDEX™
- The Microbiota-based Drug RBX2660 is Efficacious and Safe in Patients with Recurrent Clostridium difficile Infections: Results from 2 Controlled Clinical Trials
- Altering the Microbiome: Patients with a Successful Outcome Following Microbiota-Based RBX2660 Treatment Trend Toward Human Microbiome Project Healthy Subjects’ Profile
- There is No Association Between Patient Outcomes and Demographics in an Open-Label Safety and Efficacy Study of RBX2660, a Microbiota-Based Drug for Recurrent Clostridium difficile Infection
- Successful Response to Microbiota-Based Drug RBX2660 in Patients with Recurrent Clostridium difficile Infection is Associated with More Pronounced Alterations in Microbiome Profile
- Microbiome Profile is Distinct in Patients with Successful Response to Microbiota-Based Drug RBX2660 Relative to Placebo Responders
- RBX2660 is Safe, Superior to Antibiotic-Treated Controls for Preventing Recurrent difficile, and May Rehabilitate Patient Microbiomes: Open Label Trial Results
- Meta-Analysis of Response Rates Among Placebo-Treated Patients from Five Clinical Trials of Experimental Recurrent Clostridium difficile Therapeutics
- Resetting the Microbial Landscape: Donor Microbiome Engraftment in Patients Treated with RBX2660 for Multi-Recurrent Clostridium difficile Infection
- Changing the Microbiome: Patients with a Successful Outcome Following Microbiota-Based RBX2660 Treatment Trend Toward Human Microbiome Project Healthy Subjects’ Profile
- Donors are Universal in the Fight Against Clostridium difficile: Results from Two Trials Investigating the Safety and Efficacy of RBX2660, a Microbiota-based Drug
- Lack of Association with Patient Demographics and Outcomes in PUNCH CD 2, a Randomized Controlled Trial of RBX2660, a Microbiota-based Drug for Recurrent Clostridium difficile Infection
- Impact of RBX2660 on the Intestinal Microbiota of Patients with Recurrent Clostridium difficile Infection Enrolled in the Randomized, Placebo-Controlled PUNCH CD 2 Trial
- Efficacy and Safety of RBX2660 for the Prevention of Recurrent Clostridium difficile Infection: Results of the PUNCH CD 2 Trial
- Placebo Responders in a Randomised Controlled Trial of RBX2660 for Recurrent C. Difficile Infection: Predictive Value of 16s rRNA Microbiome Analysis
- Does the Donor Matter? Results from PUNCH CD 2, a Randomized Controlled Trial of a Microbiota-based Drug for Recurrent Clostridium difficile Infection
- Placebo Response in a Randomized Controlled Trial of a Microbiota-based Drug Targeted at Recurrent C. difficile Infection: Results of the PUNCH CD 2
- Durable Prevention of Recurrent C. difficile Infection with RBX2660: Results of the PUNCH CD 2 Trial
- Infectious Threats in “Healthy” Donors: Results of a Donor Screening Program for a Next-Generation FMT
- Increased Microbial Diversity Found in Successful Recipients of Next-Generation FMT for Recurrent Clostridium difficile Infection
- Assessing Infectious Threats in “Healthy” FMT Donors: Results of an Assessment Program to Support a Next-Generation Drug for Recurrent Clostridium difficile Infection
- Increased Microbial Diversity Found in Successful vs. Unsuccessful Recipients of Next-Generation FMT for Recurrent Clostridium difficile Infection
- Does the Donor Matter? Donor vs. Patient Effects in the Outcome of Next-Generation Fecal Transplant for Recurrent Clostridium difficile Infection
- Successful Implementation of a Phase 2 Study of a Novel Microbiota-based drug for Recurrent Clostridium difficile Infection
- Results of the Phase 2 PUNCH™ CD Safety Study of RBX2660 (microbiota suspension) for Recurrent C. difficile Infection
- Clearance of Vancomycin-Resistant Enterococcus Concomitant with Administration of a Microbiota-Based Drug Targeted at Recurrent Clostridium difficile Infection
- RBX2660 (microbiota suspension) for Recurrent C. difficile Infection: 60-Day Interim Analysis of the PUNCH-CD Phase 2 Safety Study
- Enema Administration of RBX2660 (microbiota suspension) for Recurrent C. difficile Infection: Lessons Learned from the PUNCH CD Study
- Next Generation Fecal Transplant for Recurrent C. difficile Infection with and without Antibiotic Pre-Treatment: Lessons Learned from the PUNCH CD Phase 2 Safety Study
- Who Seeks a Fecal Microbiota Transplant for Recurrent C. difficile Infection?: Patient Profile of the PUNCH™ CD Study
- RBX2660 (microbiota suspension) for Recurrent C. difficile Infection: 60-Day Interim Analysis of the PUNCH-CD Phase 2 Safety Study
- Evaluation of Health-Related Quality of Life in Patients Treated with RBX2660 (microbiota suspension) for Recurrent C. difficile Infection
- Microbiota Restoration Therapy Journal Articles
- Durable reduction of Clostridioides difficile infection recurrence and microbiome restoration after treatment with RBX2660: results from an open-label phase 2 clinical trial
- Development and Validation of a Novel Microbiome-Based Biomarker of Post-antibiotic Dysbiosis and Subsequent Restoration
- RBX7455, a Non-frozen, Orally Administered Investigational Live Biotherapeutic, Is Safe, Effective, and Shifts Patients’ Microbiomes in a Phase 1 Study for Recurrent Clostridioides difficile Infections
- The effect of microbiota-based investigational drug RBX2660 on the gut microbiome and resistome revealed by a placebo-controlled clinical trial
- Restoration of Bacterial Microbiome Composition and Diversity Among Treatment Responders in a Phase 2 Trial of RBX2660: An Investigational Microbiome Restoration Therapeutic
- Results From a Randomized, Placebo-Controlled Clinical Trial of a RBX2660—A Microbiota-Based Drug for the Prevention of Recurrent Clostridium difficile Infection
- Clearance of Vancomycin-Resistant Enterococcus Concomitant With Administration of a Microbiota-based Drug Targeted at Recurrent Clostridium difficile Infection
- Does the donor matter? Donor vs patient effects in the outcome of a next generation microbiota-based drug trial for recurrent Clostridium difficile infection
- Safety and Durability of RBX2660 (Microbiota Suspension) for Recurrent Clostridium difficile Infection: Results of the PUNCH CD Study
- Microbiota Restoration Therapy Posters
- Interim Analysis of a Phase 3 Open-Label Study Indicates Safety and Efficacy of RBX2660, an Investigational Live Biotherapeutic, in a “Real-world” Population of Patients with Recurrent Clostridioides difficile Infection
- Response to Microbiota-Based Drug RBX2660 is Associated with Reduction in Antimicrobial Resistance Genes in Patients with Recurrent Clostridioides difficile Infections
- Improvement of MICROBIOME HEALTH INDEX™ in Patients with Recurrent Clostridioides difficile Infections Following RBX2660 Treatment is Associated with a Reduction in Antimicrobial Resistance Genes
- RBX7455 – A Non-frozen, Lyophilized, Oral Microbiota-based Drug Reduces Clostridrium difficile Infection Recurrence and Restores Patients’ Microbiomes
- Evaluating a Prototype MICROBIOME HEALTH INDEX™ (MHI™) as a Measure of Microbiome Restoration Using Data Derived From Published Studies of Fecal Microbiota Transplant to Treat recurrent Clostridium difficile Infections (rCDI)
- Prevention of Recurrent Clostridium difficile at Six Months Following Treatment with Microbiota-based Therapy RBX2660: Durability Results From a Phase 2 Open-label Study
- Perspectives on the PUNCH CD Trial of a Microbiota-Based Drug Targeted at Recurrent C. diff. Infection
- Regulatory Considerations in Commercializing a Non-Antibiotic Microbiota-Based Drug Targeted for Recurrent Clostridium difficile Infection
- Microbiota Restoration Therapy Presentations
- Microbiota and Microbiota Restoration for Recurrent C. diff Infections
- Alterations in Microbial Diversity are Associated with Treatment Success with RBX2660, a Microbiota-Based Drug for the Prevention of Recurrent Clostridium difficile Infection: Results from PUNCH CD 2: a Randomized Double-Blind Placebo-Controlled Trials
- Consistent and Reproducible Production of a Microbiota-based Drug for Recurrent C. difficile Infection: Application of a Novel Diagnostic for Dysbiosis
- RBX2660, A Microbiota-Based Drug for the Prevention of Recurrent Clostridium difficile Infection, Is Safe and Effective: Results from a Randomised, Double-Blinded, Placebo-Controlled Trial
- Press Releases
- Ferring Presents Complete Data across Five RBX2660 Trials Demonstrating Consistent and Durable Efficacy in Recurrent C. difficile Infection, as Well as Multiple Analyses Demonstrating Positive Shifts in Microbiome Properties
- Ferring to Present Award-Winning, Landmark Research for Investigational Microbiota-Based Live Biotherapeutic RBX2660 at IDWeek 2021
- Ferring and Rebiotix Present Positive Interim Phase 3 Results from Open-Label Study of Investigational Microbiota-based Live Biotherapeutic RBX2660 at Digestive Disease Week® (DDW)
- Ferring and Rebiotix Present Landmark Phase 3 Data Demonstrating Superior Efficacy of Investigational RBX2660 Versus Placebo to Reduce Recurrence of C. difficile Infection
- Ferring, Rebiotix and MyBiotics Collaborate to Develop Live Microbiome-Based Therapeutics in Reproductive Medicine and Maternal Health
- Ferring, Rebiotix and MyBiotics Collaborate to Develop Live Microbiome-Based Therapeutics in Reproductive Medicine and Maternal Health
- Ferring Pharmaceuticals to Present New Microbiome Research Data at IDWeek 2020
- Rebiotix and Ferring announce world’s first with positive preliminary pivotal Phase 3 data for investigational microbiome-based therapy RBX2660
- Rebiotix, a Ferring Company, Completes Enrollment for First-Ever, Pivotal Phase 3 Clinical Trial of Microbiota-based RBX2660
- Rebiotix, Inc. and Karolinska Institutet Expand Partnership to Shape the Future of Microbiome Research
- Rebiotix Leaders to Discuss Microbiome Product Development Challenges and Regulation at Microbiome Movement – Drug Development Summit 2019
- Response to FDA Safety Alert Regarding the Use of Fecal Microbiota for Transplantation
- Microbiota Restoration Takes the Podium at DDW 2019: Investigational Microbiota-Based Therapies for Recurrent C. diff Highlighted
- MICROBIOME HEALTH INDEX™ Platform to be Presented at Gut Microbiota for Health Summit 2019
- Rebiotix, C. Diff Foundation Commend State of Minnesota for Declaring November Clostridium difficile Awareness Month
- Rebiotix MICROBIOME HEALTH INDEX™ Data to be Presented at United European Gastroenterology Annual Conference
- Baylor, Rebiotix Find Patient Microbiome Signatures That Differentiate Disease
- Rebiotix Clinical, Microbiome Data from First-In-Class Microbiota Restoration Therapy to Be Presented at IDWeek 2018
- MICROBIOME HEALTH INDEX™ Platform, Outcomes of Rebiotix’s RBX7455 Oral Formulation To Be Featured in Rapid Fire and Poster Sessions at ASM Microbe 2018
- Rebiotix Microbiota Restoration Therapy™ Products, MICROBIOME HEALTH INDEX™ to Take Center Stage at Digestive Disease Week 2018
- Rebiotix’s President and CEO, Lee Jones to Participate in Microbiome-Focused Panel at the 2018 BIO International Convention
- Rebiotix Presents Posters at ECCMID 2018 Highlighting MICROBIOME HEALTH INDEX™ Value Potential and RBX2660 Phase 2 Clinical Program Data
- Ferring acquires innovative biotechnology company and microbiome pioneer Rebiotix Inc.
- Rebiotix’s Lee Jones to Receive TRUST 2018 Courageous Women in Health Care Award
- Rebiotix’s Chief Scientific Officer, Ken Blount, Ph.D., to Present at Microbiome Therapeutics Europe
- Minnesota researchers help unlock ‘gut science’ cures
- Rebiotix Develops MICROBIOME HEALTH INDEX™ to Identify Indicators for Microbiome Restoration
- Rebiotix Highlights 2017 Achievements and 2018 Objectives
- Rebiotix and CoreBiome Collaborate on Evaluating Microbiomes of Patients Treated with Microbiota Restoration Therapy™
- Rebiotix Participating in Multiple Events During J.P. Morgan 36th Annual Healthcare Conference 2018 Week
- Rebiotix Announces Expansion of Phase 1 Trial of the Company’s Oral Capsule Microbiota Product, RBX7455, Following Successful Completion of Initial Study Arms
- Rebiotix to Present at 29th Annual Piper Jaffray Healthcare Conference
- Rebiotix and the C. diff. Foundation Applaud the State of Minnesota as it Declares November C. Difficile Infection Awareness Month
- New Clinical Data and Microbiome Research from Rebiotix’s Phase 2 Program for RBX2660 Highlighted at the World Congress of Gastroenterology at ACG2017
- Rebiotix Announces New RBX2660 Data Including a Novel Microbiome Biomarker Analysis to be Presented at the World Congress of Gastroenterology at ACG2017
- Presentations at ID Week™ 2017 Highlight Clinical Results and Microbiome Analysis of Patients Treated in Rebiotix’s RBX2660 Phase 2 Studies
- Rebiotix Appoints Edward S. Burd, Ph.D., to Head of Regulatory Affairs
- Rebiotix to Present at BioCentury’s 24th Annual NewsMakers in the Biotech Industry Conference
- Rebiotix Announces First Patient Enrolled in Phase 3 Clinical Trial of RBX2660 for the Prevention of Recurrent Clostridium difficile Infection
- Rebiotix Continues Management Team Expansion with Appointment of Greg Fluet as Chief Business Officer
- Rebiotix Data Presented at ASM Microbe 2017 Show RBX2660 Treated Patients’ Clinical Success Correlates with Improved Microbiome Diversity
- Rebiotix’s Phase 3 Ready RBX2660 to be Featured in Multiple Posters at ASM Microbe 2017
- Rebiotix’s Phase 3 Ready RBX2660 to be Featured in Multiple Sessions at Digestive Disease Week 2017
- Rebiotix Reports Positive Top Line Data from Open-Label Phase 2 Trial of RBX2660 in Recurrent Clostridium difficile
- Rebiotix to Present at Two Investor Conferences
- Rebiotix to Present at BIO CEO & Investor Conference
- Rebiotix Treats First Patient in Phase 1 Study of RBX7455, an Orally Delivered Broad-Spectrum Non-Frozen Microbiota Capsule for Recurrent Clostridium difficile Infection
- Rebiotix Appoints Ken F. Blount, Ph.D., Head of External Research
- Rebiotix to Present at Piper Jaffray 28th Annual Healthcare Conference
- Data from Rebiotix’s Phase 2b Trial of Lead Microbiota-Based Drug Candidate, RBX2660, to be Featured in Late-Breaking Oral Presentation at UEG Week 2016
- Rebiotix Receives Patent from the USPTO for Microbiota Restoration Therapy
- Rebiotix to Present at BioCentury’s 23rd Annual NewsMakers in the Biotech Industry Conference
- Rebiotix and Washington University Treat First Patient with Urinary Tract Infection Utilizing Investigational RBX2660 to Potentially Reverse Multidrug Resistant Organisms
- Rebiotix and McMaster Children’s Hospital Announce First Patient Treated in Largest Randomized Clinical Trial of Fecal Microbial Transplant (FMT) for Pediatric Ulcerative Colitis
- Rebiotix Named 2015 Tekne Award Winner
- Rebiotix Completes Enrollment in Phase 2 Trial of a Microbiota Restoration Therapy (MRT) for the Treatment of Recurrent Clostridium difficile Infection
- Rebiotix Receives Breakthrough Therapy Designation for RBX2660 – A Microbiota Restoration Therapy™ (MRT™) Drug Platform for the Treatment of Recurrent Clostridium difficile Infection
- Rebiotix Announces First-Ever Randomized Study of a Microbiota-based Drug for Recurrent Clostridium difficile Infection under an FDA IND
- Rebiotix Presents Additional Results of PUNCH™ CD Study of Microbiota-based Drug Candidate for Recurrent C. difficile Infection at ACG 2014
- Study Shows Rebiotix Microbiota-based Drug Candidate Targeted at Recurrent C. difficile Infection is Highly Effective
- PUNCH CD Study Drug Targeting Recurrent C. difficile Infection to be Presented at IDWeek 2014
- Rebiotix Inc. Receives $25M for Series B Funding
- Rebiotix to Present at 2014 BIO International Convention
- Rebiotix Completes Enrollment in Phase 2 Clinical Trial of New Drug for the Treatment of Recurrent Clostridium difficile-Associated Diarrhea
- Rebiotix Wins 2013 Leaders in Health Care Award
- Rebiotix Named Finalist for 2013 Leaders in Health Care Awards
- Rebiotix Receives FDA IND Approval to Begin Phase 2 Trial of Pioneering Microbiota Restoration Therapy
- FDA Grants Fast Track Designation to Rebiotix for its Microbiota Product for Recurrent Clostridium difficile Infection
- Rebiotix Begins Clinical Trial of Therapy for the Treatment of RecurrentClostridium difficile-Associated Diarrhea
- Rebiotix Inc. Hires Ryan Gordon as Vice President
- Dr. William McGuire, Former UnitedHealth Group CEO, Joins Rebiotix Inc. Board of Directors
- White Papers Microbiota Restoration Therapy